Oroxylin a reverses multi‐drug resistance of human hepatoma BEL7402/5‐FU cells via downregulation of P‐glycoprotein expression by inhibiting NF‐κB signaling pathway

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Carcinogenesis

• Publication date

  2012-02-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/mc.20789PMID 21557331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells

  2011cited by this paper
• Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols

  2010cited by this paper
• Reversal of multidrug resitance by natural substances from plants.

  2010cited by this paper
• Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation

  2010cited by this paper
• Differential Regulation of Interleukin-1 Receptor-associated Kinase-1 (IRAK-1) and IRAK-2 by MicroRNA-146a and NF-κB in Stressed Human Astroglial Cells and in Alzheimer Disease*

  2010cited by this paper
• Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice

  2010cited by this paper
• MAC-related mitochondrial pathway in oroxylin-A-induced apoptosis in human hepatocellular carcinoma HepG2 cells.

  2009cited by this paper
• Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.

  2009cited by this paper
• Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells.

  2009cited by this paper
• Evaluation of the flavonoid oroxylin A as an inhibitor of P-glycoprotein-mediated cellular efflux.

  2009cited by this paper
• Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU.

  2008cited by this paper
• Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells.

  2008cited by this paper
• Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression.

  2008cited by this paper
• ADMA induces monocyte adhesion via activation of chemokine receptors in cultured THP-1 cells.

  2008cited by this paper
• Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications.

  2007cited by this paper
• Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.

  2006cited by this paper
• Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.

  2006cited by this paper
• Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography.

  2005cited by this paper
• A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway.

  2004cited by this paper
• Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line.

  2004cited by this paper
• Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.

  2004cited by this paper
• Substrate-induced Conformational Changes in the Transmembrane Segments of Human P-glycoprotein

  2003cited by this paper
• Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

  2003cited by this paper
• NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells

  2003cited by this paper
• Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

  2003cited by this paper
• Quantification of doxorubicin and validation of reversal effect of tea polyphenols on multidrug resistance in human carcinoma cells

  2003cited by this paper
• Strategies for reversing drug resistance

  2003cited by this paper
• Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells.

  2002cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Suppressive Effects of Edible Thai Plants on Superoxide and Nitric Oxide Generation.

  2002cited by this paper
• Recent advances in the discovery of flavonoids and analogs with high‐affinity binding to P‐glycoprotein responsible for cancer cell multidrug resistance

  2002cited by this paper
• Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells.

  2001cited by this paper
• 2-Acetylaminofluorene Up-regulates Rat mdr1bExpression through Generating Reactive Oxygen Species That Activate NF-κB Pathway*

  2001cited by this paper
• Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.

  2000cited by this paper
• Multidrug resistance transporters and modulation

  2000cited by this paper
• Multicellular resistance: a paradigm for clinical resistance?

  2000cited by this paper
• Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response.

  2000cited by this paper
• Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation.

  2000cited by this paper
• Resistance to the chemosensitizer verapamil in a multi‐drug‐resistant (MDR) human multiple myeloma cell line

  1996cited by this paper

• First-in-class drug oroxylin A tablets for treating hepatic and gastrointestinal disorders: from preclinical development to clinical research.

  2025cites this paper
• Elevated BCRP Transporter and Altered NF‐кB Pathway Mediate Zoledronic Acid Resistance in MCF‐7 Cells

  2025cites this paper
• Cellular and molecular mechanisms of oroxylin A in cancer therapy: Recent advances.

  2024cites this paper
• Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers.

  2024cites this paper
• Oroxylin A: Nature's Arsenal Against Liver Fibrosis, Cancer, and Inflammatory Diseases

  2023cites this paper
• Modulation of diverse oncogenic signaling pathways by oroxylin A: An important strategy for both cancer prevention and treatment.

  2022cites this paper
• Oroxylin A: A Promising Flavonoid for Prevention and Treatment of Chronic Diseases

  2022cites this paper
• P-glycoprotein mediated interactions between Chinese materia medica and pharmaceutical drugs

  2021cites this paper
• Phosphatidylinositol-3-kinase/Protein Kinase B Signaling Pathway: A Pivotal Factor for Stimulating Multidrug Resistance in Hepatocellular Carcinoma Cells

  2021cites this paper
• Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery

  2021influential citation
• Konjac glucomannan reverses multi-drug resistance of HepG2/5-FU cells by suppressing AKT signaling and increasing p53 expression

  2020cites this paper
• Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription

  2020cites this paper
• Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.

  2020cites this paper
• Gambogenic acid reverses P-glycoprotein mediated multidrug resistance in HepG2/Adr cells and its underlying mechanism.

  2019cites this paper
• Spica Prunellae Extract Enhances Fluorouracil Sensitivity of 5-Fluorouracil-Resistant Human Colon Carcinoma HCT-8/5-FU Cells via TOP2α and miR-494

  2019cites this paper
• Roles of integrin in tumor development and the target inhibitors.

  2019cites this paper
• Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway

  2019cites this paper
• β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.

  2019cites this paper
• Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia‐inducible factor 1α/hedgehog pathway under hypoxia

  2019cites this paper
• Regulation of ABCG2 by nuclear factor kappa B affects the sensitivity of human lung adenocarcinoma A549 cells to arsenic trioxide.

  2018cites this paper
• Gamma-tocotrienol reverses multidrug resistance of breast cancer cells with a mechanism distinct from that of atorvastatin.

  2017cites this paper
• DHPAC, a novel synthetic microtubule destabilizing agent, possess high anti-tumor activity in vincristine-resistant oral epidermoid carcinoma in vitro and in vivo.

  2017cites this paper
• Sinapine reverses multi-drug resistance in MCF-7/dox cancer cells by downregulating FGFR4/FRS2α-ERK1/2 pathway-mediated NF-κB activation.

  2016cites this paper
• Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.

  2016cites this paper
• Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: More than just down-regulation of MDR1

  2016cites this paper
• BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin

  2016cites this paper
• Osthole shows the potential to overcome P-glycoprotein‑mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway.

  2016cites this paper
• TAS-102 an Emerging Oral Fluoropyrimidine.

  2016cites this paper
• Overview of Oroxylin A: A Promising Flavonoid Compound

  2016influential citation
• Aromatic heterocyclic esters of podophyllotoxin exert anti-MDR activity in human leukemia K562/ADR cells via ROS/MAPK signaling pathways.

  2016cites this paper
• Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.

  2015cites this paper
• Schisandrin A enhances the cytotoxicity of doxorubicin by the inhibition of nuclear factor-kappa B signaling in a doxorubicin-resistant human osteosarcoma cell line

  2015cites this paper
• Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells.

  2015cites this paper
• Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells

  2015cites this paper
• GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS Axis in hepatocellular carcinoma

  2015cites this paper
• Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro

  2014cites this paper
• Dioscin enhances methotrexate absorption by down-regulating MDR1 in vitro and in vivo.

  2014cites this paper
• CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.

  2014cites this paper
• Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway.

  2014cites this paper
• Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF‐1α and glycolysis, by inhibiting PI3K/Akt signaling pathway

  2014cites this paper
• Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway

  2014cites this paper
• Dioscin restores the activity of the anticancer agent adriamycin in multidrug-resistant human leukemia K562/adriamycin cells by down-regulating MDR1 via a mechanism involving NF-κB signaling inhibition.

  2013cites this paper
• Drug resistance associates with activation of Nrf2 in MCF‐7/DOX cells, and wogonin reverses it by down‐regulating Nrf2‐mediated cellular defense response

  2013cites this paper
• Small molecule inhibitors of multidrug resistance gene (MDR1) expression: preclinical evaluation and mechanisms of action.

  2013cites this paper
• Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II.

  2013cites this paper
• Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells.

  2013cites this paper
• Combinations of plant polyphenols & anti-cancer molecules: a novel treatment strategy for cancer chemotherapy.

  2013cites this paper
• Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest.

  2013cites this paper
• Grape Seed Procyanidin Reversal of P-glycoprotein Associated Multi-Drug Resistance via Down-regulation of NF-κB and MAPK/ERK Mediated YB-1 Activity in A2780/T Cells

  2013cites this paper
• The Noncytotoxic Dose of Sorafenib Sensitizes Bel-7402/5-FU Cells to 5-FU by Down-Regulating 5-FU-Induced Nrf2 Expression

  2013cites this paper
• Activation of the unfolded protein response contributed to the selective cytotoxicity of oroxylin A in human hepatocellular carcinoma HepG2 cells.

  2012cites this paper
• Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinβ1 and its related pathway.

  2012cites this paper